Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(7), 2090-2110; doi:10.3390/ph3072090
Review

Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development

Received: 10 June 2010; in revised form: 28 June 2010 / Accepted: 2 July 2010 / Published: 5 July 2010
(This article belongs to the Special Issue Antiepileptic Drugs)
View Full-Text   |   Download PDF [159 KB, uploaded 5 July 2010]
Abstract: Epilepsy is a serious neurological disorder that affects around 50 million people worldwide. Almost 30% of epileptic patients suffer from pharmacoresistance, which is associated with social isolation, dependent behaviour, low marriage rates, unemployment, psychological issues and reduced quality of life. Currently available antiepileptic drugs have a limited efficacy, and their negative properties limit their use and cause difficulties in patient management. Antiepileptic drugs can provide only symptomatic relief as these drugs suppress seizures but do not have ability to cure epileptogenesis. The long term use of antiepileptic drugs is limited due to their adverse effects, withdrawal symptoms, deleterious interactions with other drugs and economic burden, especially in developing countries. Furthermore, some of the available antiepileptic drugs may even potentiate certain type of seizures. Several in vivo and in vitro animal models have been proposed and many new antiepileptic drugs have been marketed recently, but large numbers of patients are still pharmacoresistant. This review will highlight the difficulties in treatment and management of epilepsy and the limitations of available antiepileptic drugs and animal seizure models.
Keywords: antiepileptic; anticonvulsant; seizure; pharmacoresistance; refractory seizures antiepileptic; anticonvulsant; seizure; pharmacoresistance; refractory seizures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wahab, A. Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development. Pharmaceuticals 2010, 3, 2090-2110.

AMA Style

Wahab A. Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development. Pharmaceuticals. 2010; 3(7):2090-2110.

Chicago/Turabian Style

Wahab, Abdul. 2010. "Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development." Pharmaceuticals 3, no. 7: 2090-2110.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert